These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 9688450)

  • 61. Factors determining resistance to beta-lactam combined with beta-lactamase inhibitors in Escherichia coli.
    Reguera JA; Baquero F; Pérez-Díaz JC; Martínez JL
    J Antimicrob Chemother; 1991 May; 27(5):569-75. PubMed ID: 1653204
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effect of pO2 and pH on synergy of tazobactam and beta-lactam antibiotics against beta-lactamase producing Enterobacteriaceae.
    König C; Blaser J
    J Antimicrob Chemother; 1995 Sep; 36(3):513-9. PubMed ID: 8830015
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Efficacy and safety of piperacillin/tazobactam in intra-abdominal infections.
    Vestweber KH; Grundel E
    Eur J Surg Suppl; 1994; (573):57-60. PubMed ID: 7524797
    [TBL] [Abstract][Full Text] [Related]  

  • 64. β-Lactamase Inhibitors Enhance the Synergy between β-Lactam Antibiotics and Daptomycin against Methicillin-Resistant Staphylococcus aureus.
    Henson KE; Yim J; Smith JR; Sakoulas G; Rybak MJ
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821441
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Fundamental and clinical studies on beta-lactamase inhibitors].
    Niki Y
    Nihon Rinsho; 2001 Apr; 59(4):771-6. PubMed ID: 11305004
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe.
    Livermore DM; Yuan M
    J Antimicrob Chemother; 1996 Sep; 38(3):409-24. PubMed ID: 8889716
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Orally administered recombinant metallo-beta-lactamase preserves colonization resistance of piperacillin-tazobactam-treated mice.
    Stiefel U; Harmoinen J; Koski P; Kääriäinen S; Wickstrand N; Lindevall K; Pultz NJ; Bonomo RA; Helfand MS; Donskey CJ
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5190-1. PubMed ID: 16304203
    [No Abstract]   [Full Text] [Related]  

  • 69. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
    J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Superior effect of tazobactam/piperacillin compared to piperacillin on beta-lactamase-producing Pseudomonas aeruginosa.
    Nishida K; Higashitani F; Hyodo A
    Chemotherapy; 1997; 43(3):171-8. PubMed ID: 9142457
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria.
    D'Angelo RG; Johnson JK; Bork JT; Heil EL
    Expert Opin Pharmacother; 2016; 17(7):953-67. PubMed ID: 26891857
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
    Bethel CR; Hujer AM; Helfand MS; Bonomo RA
    FEMS Microbiol Lett; 2004 May; 234(1):99-103. PubMed ID: 15109726
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Laboratory and clinical studies on tazobactam/piperacillin in the field of pediatrics].
    Kuno K; Ogawa A; Hayakawa F; Miyajima Y; Takahashi H; Okumura A; Kato T; Itomi K
    Jpn J Antibiot; 1998 Jun; 51(6):395-406. PubMed ID: 9755829
    [TBL] [Abstract][Full Text] [Related]  

  • 74.
    Goodlet KJ; Nicolau DP; Nailor MD
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Antibacterial activity of piperacillin and tazobactam against beta-lactamase-producing clinical isolates.
    Cullmann W; Stieglitz M
    Chemotherapy; 1990; 36(5):356-64. PubMed ID: 2170081
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Bacteriological and clinical evaluation tazobactam/piperacillin in infectious diseases in surgical field].
    Shinagawa N; Yura J; Mashita K; Matsuno S; Rikiyama T; Hirayama T; Tanaka T; Otsuka K; Iwai S; Nakagawa Y
    Jpn J Antibiot; 1995 Mar; 48(3):346-67. PubMed ID: 7752449
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Inhibition of OXA-1 beta-lactamase by penems.
    Bethel CR; Distler AM; Ruszczycky MW; Carey MP; Carey PR; Hujer AM; Taracila M; Helfand MS; Thomson JM; Kalp M; Anderson VE; Leonard DA; Hujer KM; Abe T; Venkatesan AM; Mansour TS; Bonomo RA
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3135-43. PubMed ID: 18559643
    [TBL] [Abstract][Full Text] [Related]  

  • 78. An observational study on the epidemiology of respiratory tract bacterial pathogens and their susceptibility to four injectable beta-lactam antibiotics: piperacillin, piperacillin/tazobactam, ceftazidime and ceftriaxone.
    Varotto F; Maria GD; Azzaro R; Bellissima P; Amato R; Fogliani V; Muscianisi G; Vitale S; Girbino G; Andò F; Laganà P; Delia S; Jacoviello C; Maierna G; Pezza A; Covelli I; Magrì M; Napoletano G; Rossi A; Marone P; Sanguinetti C; Pela R; Tedeschi D; Viola B; Cicciarella S; Messina G; Rizza S; Fraschini F
    J Chemother; 2001 Aug; 13(4):413-23. PubMed ID: 11589485
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
    Xiao YH; Hu YJ
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
    [No Abstract]   [Full Text] [Related]  

  • 80. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam.
    Sörgel F; Kinzig M
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():39-60. PubMed ID: 8383655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.